Mengchao Hepatobiliary Hospital of Fujian Medical University
福建医科大学孟超肝胆医院
Listed for 2 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Mengchao Hepatobiliary Hospital of Fujian Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatocellular carcinoma肝细胞癌84 papers led3 open trials led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 84 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.
6 hospitals in Fuzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 14
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06280105
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingNeoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06349317
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2022-08
- Registry
- NCT05409482
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07478302
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Nanning
- RecruitingMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07479485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07521852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai
- RecruitingA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Registry
- NCT07547553
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingTriple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06561399
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou
- RecruitingNeoadjuvant Triple Therapy for Resectable HCC
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06569498
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingTriple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06602011
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led84
- Calreticulin Enhances Therapeutic Immune Responses of Dry Thermostat-Stressed Hepatocellular Carcinoma Cell Vaccine.
- Identification of a pyroptosis-related long noncoding RNA signature for determining the prognosis and immune status of hepatocellular carcinoma patients.
- Porous platinum nanozyme-amplified capacitance immunoassay for alpha-fetoprotein with hepatocellular carcinoma on an interdigitated gold micro-comb array.
- Prognostic comparison between LNM and MaVI of hepatocellular carcinoma: a multicenter population-based propensity scores matching study.
- Knocking Down SKA1 Inhibits Hepatocellular Carcinoma Progression via Apoptosis: Integrating Single-Cell Transcriptomics With In Vivo and In Vitro Validation.
- Mesoporous cerium oxide nanoenzyme for Efficacious impeding tumor and metastasis via Conferring resistance to anoikis.
- The APP Score: A simple serum biomarker model to enhance prognostic prediction in hepatocellular carcinoma.
- RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer.
- Systemic therapy followed by liver resection improved prognosis of hepatocellular carcinoma associated with macrovascular invasion.
- Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.
- Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study.
- Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection.
- Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.
- Implantable artificial lymph node enables rapid in vivo neoantigen-specific T-cell generation and expansion for improving antitumor immunity.
- Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications.
- High-Throughput Proteomics Reveals a Novel Small Open Reading Frame-Encoded Peptide That Promotes Hepatocellular Carcinoma Invasion and Migration.
- Construction and validation of a novel model for guiding targeted combined immunotherapy in advanced hepatocellular carcinoma.
- Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma.
- Prognostic nutritional index is a better inflammation based prognostic marker in elderly patients with hepatocellular carcinoma after surgery.
- Evaluating the efficacy of using large language models in preoperative prediction of microvascular invasion in HCC: a multicenter study.
- Impact of metabolic dysfunction-associated fatty liver disease on survival outcomes in patients undergoing radical resection for hepatitis B virus-related hepatocellular carcinoma.
- Development and validation of an Immune-related Gene-based model for predicting prognosis and immunotherapy outcomes in hepatocellular carcinoma patients.
- Biomimetic Responsive Nanoconverters with Immune Checkpoint Blockade Plus Antiangiogenesis for Advanced Hepatocellular Carcinoma Treatment.
- Multifunctional Biomimetic Nanocarriers for Dual-Targeted Immuno-Gene Therapy Against Hepatocellular Carcinoma.
- Surgical Decision-Making Considerations in Hepatocellular Carcinoma Resection: Safety and Efficacy.
- Impact of Hepatic Pedicle Clamping on Long-Term Survival Following Hepatectomy for Hepatocellular Carcinoma: Stratified Analysis Based on Intraoperative Blood Transfusion Status.
- The Effect of Microvascular Invasion on Hepatocellular Carcinoma With Portal Vein Tumor Thrombus After Hepatectomy: A Retrospective Study.
- RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion.
- Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.
- The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma.
- TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis.
- Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.
- A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma.
- Proteomic Analysis Identifies GSN as a Noninvasive Circulating Serum Biomarker for Predicting Early Recurrence of Hepatocellular Carcinoma.
- Nomogram for predicting early recurrence of hepatocellular carcinoma with narrow resection margin.
- Safety and efficacy of interventional embolization in cirrhotic patients with refractory hepatic encephalopathy associated with spontaneous portosystemic shunts.
- Chalcomoracin promotes apoptosis and endoplasmic reticulum stress in hepatocellular carcinoma cells.
- Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
- Development and validation a radiomics nomogram for predicting thymidylate synthase status in hepatocellular carcinoma based on Gd-DTPA contrast enhanced MRI.
- Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study.
- Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection.
- Prognosis value of microscopic bile duct invasion in hepatocellular carcinoma: A multicenter study.
- Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy.
- Navoximod modulates local HSV-1 replication to reshape tumor immune microenvironment for enhanced immunotherapy via an injectable hydrogel.
- Prevalence, clinical characteristics, and outcomes of spontaneous portosystemic shunt in patients with hepatitis B-related cirrhosis: A multicenter study from China.
- Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression.
- Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma.
- Association of primary tumor location with long-term oncological prognosis following hepatectomy for hepatocellular carcinoma:A multicenter propensity score matching analysis.
- Analysis of conditional survival in primary hepatocellular carcinoma after narrow-margin hepatectomy: a large-sample, dual-centre, retrospective study.
- Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a r
- Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propens
- Revolutionising hepatocellular carcinoma surveillance: Harnessing contrast-enhanced ultrasound and serological indicators for postoperative early recurrence prediction.
- Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma.
- Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC).
- Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma.
- Normalization of Tumor Vessels by Lenvatinib-Based Metallo-Nanodrugs Alleviates Hypoxia and Enhances Calreticulin-Mediated Immune Responses in Orthotopic HCC and Organoids.
- Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
- Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application.
- Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.
- Efficacy of Adjuvant Transarterial Chemoembolization Combined Antiviral Therapy for HBV-Related HCC with MVI after Hepatic Resection: A Multicenter Study.
- Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
- Immune Analysis and Small Molecule Drug Prediction of Hepatocellular Carcinoma Based on Single Sample Gene Set Enrichment Analysis.
- Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis.
- The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
- Dysregulation of global circular RNA abundance regulated by spliceosomes predicts prognosis in hepatocellular carcinoma.
- Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.
- Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data.
- Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma.
- Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression.
- Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study.
- Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.
- Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
- A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.
- Accurate transcriptome assembly by Nanopore RNA sequencing reveals novel functional transcripts in hepatocellular carcinoma.
- Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma.
- Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection.
- Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
- Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma.
- The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study.
- A remotely controlled NIR-II photothermal-sensitive transgene system for hepatocellular carcinoma synergistic therapy.
- Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
- Redirecting natural killer cells to potentiate adoptive immunotherapy in solid tumors through stabilized Y-type bispecific aptamer.
- An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver.
- Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study.
Chinese-language papers (not in the count)3
- [Comparison of the efficacy of anatomical resection versus hepatic parenchymal preservation preference in patients with solitary small hepatocellular carcinoma and cirrhosis: a multicenter retrospective study].
- [A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma].
- [Safety and efficacy of TIPS combined with iodine-125 seed strands in the treatment of patients with hepatocellular carcinoma combined with portal vein tumor thrombosis].
All its trials on ClinicalTrials.gov, any status26
- A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
- A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
- Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Neoadjuvant Triple Therapy for Resectable HCC
- Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Prospective Surveillance for Very Early Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Fuzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Getting in touch
Name card to show staff or a driver
福建医科大学孟超肝胆医院
Mengchao Hepatobiliary Hospital of Fujian Medical University
福州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Mengchao Hepatobiliary Hospital; Mengchao hepatobiliary Hospital of Fujian Medical University; Mengchao Hepatobiliary Hospital of Fujian. Medical University; Mengchao Hepatobiliary Surgery Hospital; United Innovation of Mengchao Hepatobiliary Technology; First Affiliated and Mengchao Hepatobiliary Surgery Hospital